From detection to decisions: refocusing immunogenicity assessment on clinical relevance
- 4 November 2026
- journal article
- editorial
- Published by Taylor & Francis in Bioanalysis
- p. 1-4
Abstract
Immunogenicity assessment has changed enormously over the past three decades. Assays have become more sensitive and drug tolerant, technologies increasingly allow us to characterize immune response...Keywords
This publication has 28 references indexed in Scilit:
- Biosimilars in practice: best-practice immunogenicity assessment and switching/interchangeability strategies for pharmacy-led programsBioanalysis, 2026
- Harmonizing immunogenicity for AAV and LNP/mRNA modalities: best-practice panels for binding, neutralizing, and cellular assays with pre-existing immunity controlsBioanalysis, 2026
- Mitigation of pre-existing immunogenicity in ADA method developmentBioanalysis, 2026
- Early pre-existing anti-drug antibody screening in biotherapeutic development: a cross-company perspectiveBioanalysis, 2025
- Accurate quantification of anti-drug antibodies against each unique Fab of a bispecific antibody using an ECL bridging assayBioanalysis, 2025
- Augmenting immunogenicity workflows with AI and real-world evidence: failure points, tools, and a closed-loop operational blueprintBioanalysis, 2025
- Mitigating ADA matrix interferences: semiquantitative double immunoprecipitation for anti-bevacizumab antibody in plasmaBioanalysis, 2025
- Refined ADA testing strategy to overcome sRANKL interference in denosumab/FKS518 immunogenicity assessmentBioanalysis, 2025
- Immunogenicity assay supporting clinical development of RGB-19, a proposed biosimilar to RoActemra®Bioanalysis, 2025
- Addressing nonspecific interactions in a Gyrolab anti-drug antibody (ADA) assay: a case study on method optimization to improve repeatabilityBioanalysis, 2025